Recent Security Class Actions

Regeneron Pharmaceuticals Inc. Common Stock (NASDAQ: REGN)

45 Days left to seek lead plaintiff status.

Company Name:Regeneron Pharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: REGN
Class Period Start:08/01/2025
Class Period End (inclusive):05/15/2026
Filing Deadline:09/14/2026

The complaint alleges Defendants provided investors with material information concerning Regeneron’s Phase III clinical trial of Fianlimab, a LAG-3 inhibitor, in combination with cemiplimab, a PD-1 inhibitor, as a first-line treatment for metastatic or locally advanced melanoma (the “Phase III Fianlimab-Libtayo Study”). Defendants’ statements included, among other things, overwhelming confidence in the drug combination’s potential for success and a mischaracterization of the additional structural risk imposed on the study by the prolonged slowdown in event accruals.

Regeneron Pharmaceuticals Inc. Common Stock (NASDAQ: REGN) Claim Form

This field is for validation purposes and should be left unchanged.
Name(Required)
Address